<p>Aptevo Therapeutics Inc. (NASDAQ:APVO) 是一家临床阶段的生物技术公司，专注于基于其专有的 ADAPTIR™和 ADAPTIR-FLEX™平台技术开发新型免疫肿瘤治疗药物。今天宣布将进行反向股票拆分，拆分比例为 1 比 18（&#34;反向股票拆分&#34;），针对其每股面值为 0.001 美元的普通股（&#34;普通股&#34;）。</p>
<p>反向股票拆分预计将于 12 月 29 日下午 5:01（东部时间）生效（&#34;生效时间&#34;），预计普通股将在 2025 年 12 月 30 日市场开盘时以拆分调整后的基础在纳斯达克资本市场开始交易。与反向股票拆分相关的，每 18 股截至生效时间已发行和流通的普通股将自动转换为 1 股普通股。反向股票拆分不会改变普通股的交易代码&#34;APVO&#34;。</p>
<p>反向股票拆分已获得公司股东在 2025 年 7 月 24 日召开的年度股东大会（&#34;年度会议&#34;）上的批准，将在董事会的自由裁量权内在批准的参数内实施。年度会议后，最终比例于 2025 年 12 月 17 日获得公司董事会的批准。</p>
<p>反向股票拆分将把已发行的普通股数量从约 1800 万股（截至本新闻稿日期）减少到约 100 万股，具体数量将根据四舍五入进行调整，并可能在反向股票拆分生效日期之前进行额外发行。</p>
<p>反向股票拆分将影响所有已发行和流通的普通股。所有未到期的期权、限制性股票单位、认股权证和其他证券的持有人在反向拆分后将根据每种证券的条款进行调整。根据公司的股权激励计划可授予的股份数量也将适当调整。反向拆分后，普通股的面值将保持不变，仍为每股 0.001 美元。反向股票拆分不会改变普通股或优先股的授权数量。与反向股票拆分相关的不会发行零碎股份，股东如有权获得零碎股份，将有权获得现金支付（不计利息）。</p>
<p>有关反向股票拆分的更多信息，请参阅公司于 2025 年 7 月 3 日向美国证券交易委员会（&#34;SEC&#34;）提交的最终代理声明，以及公司计划在生效时间后提交的 8-K 表格的当前报告。</p>
<p><strong>关于 Aptevo Therapeutics</strong></p>
<p>Aptevo Therapeutics Inc. (NASDAQ:APVO) 是一家临床阶段的生物技术公司，专注于开发新型双特异性和三特异性免疫疗法用于癌症治疗。公司目前有两个临床候选药物。Mipletamig 目前正在 RAINIER 进行评估，这是一个针对一线急性髓性白血病的两部分 1b/2 期试验，联合标准治疗 venetoclax + azacitidine。根据孤儿药法，Mipletamig 已获得急性髓性白血病的孤儿药资格（&#34;孤儿状态&#34;）。ALG.APV-527 是一种双特异性条件性 4-1BB 激动剂，仅在同时结合 4-1BB 和 5T4 时活跃，正在与 Alligator Bioscience 共同开发，并最近在针对可能表达 5T4 的多种实体肿瘤类型的 1 期临床试验中进行评估。公司还有六个具有不同作用机制的临床前候选药物，旨在针对多种实体肿瘤。所有管线候选药物均来自两个专有平台，ADAPTIR 和 ADAPTIR-FLEX。Aptevo 的使命是改善治疗结果，改变癌症患者的生活。有关更多信息，请访问 www.aptevotherapeutics.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 “前瞻性声明”，包括管理层对公司未来预期、计划和前景的看法，符合联邦证券法下的安全港条款，包括 1995 年《私人证券诉讼改革法》。诸如 “期望”、“估计”、“预测”、“预算”、“展望”、“预期”、“打算”、“计划”、“可能”、“将”、“能够”、“应该”、“相信”、“预测”、“潜在”、“继续” 等类似表达旨在识别此类前瞻性声明。这些前瞻性声明涉及重大风险和不确定性，可能导致实际结果与预期结果存在重大差异，因此，您不应将这些前瞻性声明视为未来事件的预测。这些前瞻性声明及可能导致此类差异的因素包括但不限于我们作为持续经营实体的能力；Aptevo 的业务或前景恶化；对初步或中期数据的进一步评估或后续临床试验的不同结果；临床开发中的不良事件和意外问题及不利进展，包括在临床试验中观察到的意外安全问题；以及监管、社会、宏观经济和政治条件的变化。这些风险并非详尽无遗，公司面临已知和未知的风险。可能影响公司结果的其他风险和因素在公司向 SEC 提交的文件中列出，包括截至 2024 年 12 月 31 日的财政年度的 10-K 表格年度报告及其后续的 10-Q 表格和 8-K 表格当前报告。上述内容列出了许多但不是全部可能导致实际结果与公司在任何前瞻性声明中的预期存在差异的因素。提醒读者不要对任何前瞻性声明过度依赖，包括但不限于关于实施反向股票拆分的声明。这些报告和文件可在 www.sec.gov 上获取，并在这些报告提交或提供给 SEC 后不久可在公司网站的 “投资者” 页面 www.apvotherapeutics.com 上免费下载。任何前瞻性声明仅在本新闻稿发布之日有效，除法律要求外，公司不承担更新任何前瞻性声明以反映新信息、事件或情况的义务。</p>
<p><strong>联系方式：</strong></p>
<p>米里亚姆·韦伯·米勒</p>
<p>投资者关系与企业传播负责人</p>
<p>Aptevo Therapeutics</p>
<p>电子邮件：<strong>IR@apvo.com</strong> 或 <strong>Millerm@apvo.com</strong></p>
<p>电话：206-859-6628</p>
<p><strong>来源：</strong> Aptevo Therapeutics</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMTIzMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMTIzMw"/></p>

APVO

<p>Aptevo Therapeutics Inc.（纳斯达克代码：APVO）宣布将于 2025 年 12 月 29 日实施 1 比 18 的反向股票拆分。此次拆分将使流通股数量从 1800 万股减少至 100 万股。交易代码 “APVO” 将保持不变。反向拆分已获得股东和董事会的批准。不会发行零碎股份；将以现金支付代替。更多详细信息请参见公司的 SEC 文件</p>

<p>Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it will conduct a reverse stock split of its outstanding shares of common stock, par value $0.001 per share (&#34;Common Stock&#34;), at a ratio of 1-for-18 (the &#34;Reverse Stock Split&#34;).</p>
<div class="lb-trans"><p>Aptevo Therapeutics Inc. (NASDAQ:APVO) 是一家临床阶段的生物技术公司，专注于基于其专有的 ADAPTIR™和 ADAPTIR-FLEX™平台技术开发新型免疫肿瘤治疗药物。今天宣布将进行反向股票拆分，拆分比例为 1 比 18（&#34;反向股票拆分&#34;），针对其每股面值为 0.001 美元的普通股（&#34;普通股&#34;）。</p>
</div><p>The Reverse Stock Split is expected to become effective on December 29, at 5:01 p.m. Eastern Time (the &#34;Effective Time&#34;), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted basis, at market open on December 30, 2025. In connection with the Reverse Stock Split, every 18 shares of Common Stock issued and outstanding as of the Effective Time will be automatically converted into one share of Common Stock. No change will be made to the trading symbol for the Common Stock, &#34;APVO,&#34; in connection with the Reverse Stock Split.</p>
<div class="lb-trans"><p>反向股票拆分预计将于 12 月 29 日下午 5:01（东部时间）生效（&#34;生效时间&#34;），预计普通股将在 2025 年 12 月 30 日市场开盘时以拆分调整后的基础在纳斯达克资本市场开始交易。与反向股票拆分相关的，每 18 股截至生效时间已发行和流通的普通股将自动转换为 1 股普通股。反向股票拆分不会改变普通股的交易代码&#34;APVO&#34;。</p>
</div><p>The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on July 24, 2025 (the &#34;Annual Meeting&#34;) to be effected in the Board's discretion within approved parameters. Following the Annual Meeting, the final ratio was approved by the Company's Board on December 17, 2025.</p>
<div class="lb-trans"><p>反向股票拆分已获得公司股东在 2025 年 7 月 24 日召开的年度股东大会（&#34;年度会议&#34;）上的批准，将在董事会的自由裁量权内在批准的参数内实施。年度会议后，最终比例于 2025 年 12 月 17 日获得公司董事会的批准。</p>
</div><p>The Reverse Stock Split will reduce the number of shares of outstanding Common Stock from approximately 18 million shares (as of the date of this press release) to approximately 1 million shares, subject to adjustment for rounding, as discussed below and potential additional issuances through the effective date of the Reverse Stock Split.</p>
<div class="lb-trans"><p>反向股票拆分将把已发行的普通股数量从约 1800 万股（截至本新闻稿日期）减少到约 100 万股，具体数量将根据四舍五入进行调整，并可能在反向股票拆分生效日期之前进行额外发行。</p>
</div><p>The Reverse Stock Split will affect all issued and outstanding shares of Common Stock. All outstanding options, restricted stock units, warrants, and other securities entitling their holders to purchase or otherwise receive shares of Common Stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares available to be awarded under the Company's equity incentive plans will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.001 par value per share. The Reverse Stock Split will not change the authorized number of shares of Common Stock or preferred stock. No fractional shares will be issued in connection with the Reverse Stock Split, and stockholders who would otherwise be entitled to receive a fractional share of Common Stock will be entitled to receive a cash payment (without interest).</p>
<div class="lb-trans"><p>反向股票拆分将影响所有已发行和流通的普通股。所有未到期的期权、限制性股票单位、认股权证和其他证券的持有人在反向拆分后将根据每种证券的条款进行调整。根据公司的股权激励计划可授予的股份数量也将适当调整。反向拆分后，普通股的面值将保持不变，仍为每股 0.001 美元。反向股票拆分不会改变普通股或优先股的授权数量。与反向股票拆分相关的不会发行零碎股份，股东如有权获得零碎股份，将有权获得现金支付（不计利息）。</p>
</div><p>Additional information regarding the Reverse Stock Split is available in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (&#34;SEC&#34;) on July 3, 2025, and a Current Report on Form 8-K which the Company plans to file following the Effective Time.</p>
<div class="lb-trans"><p>有关反向股票拆分的更多信息，请参阅公司于 2025 年 7 月 3 日向美国证券交易委员会（&#34;SEC&#34;）提交的最终代理声明，以及公司计划在生效时间后提交的 8-K 表格的当前报告。</p>
</div><p><strong>About Aptevo Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Aptevo Therapeutics</strong></p>
</div><p>Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation (&#34;orphan status&#34;) for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and was most recently evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has six preclinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIRand ADAPTIR-FLEX. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.</p>
<div class="lb-trans"><p>Aptevo Therapeutics Inc. (NASDAQ:APVO) 是一家临床阶段的生物技术公司，专注于开发新型双特异性和三特异性免疫疗法用于癌症治疗。公司目前有两个临床候选药物。Mipletamig 目前正在 RAINIER 进行评估，这是一个针对一线急性髓性白血病的两部分 1b/2 期试验，联合标准治疗 venetoclax + azacitidine。根据孤儿药法，Mipletamig 已获得急性髓性白血病的孤儿药资格（&#34;孤儿状态&#34;）。ALG.APV-527 是一种双特异性条件性 4-1BB 激动剂，仅在同时结合 4-1BB 和 5T4 时活跃，正在与 Alligator Bioscience 共同开发，并最近在针对可能表达 5T4 的多种实体肿瘤类型的 1 期临床试验中进行评估。公司还有六个具有不同作用机制的临床前候选药物，旨在针对多种实体肿瘤。所有管线候选药物均来自两个专有平台，ADAPTIR 和 ADAPTIR-FLEX。Aptevo 的使命是改善治疗结果，改变癌症患者的生活。有关更多信息，请访问 www.aptevotherapeutics.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes &#34;forward-looking statements&#34;, including information about management's view of the Company's future expectations, plans and prospects, within the safe harbor provisions provided under federal securities laws, including under The Private Securities Litigation Reform Act of 1995. Words such as &#34;expect,&#34; &#34;estimate,&#34; &#34;project,&#34; &#34;budget,&#34; &#34;forecast,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;may,&#34; &#34;will,&#34; &#34;could,&#34; &#34;should,&#34; &#34;believes,&#34; &#34;predicts,&#34; &#34;potential,&#34; &#34;continue&#34; and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, our ability to continue as a going concern; a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems and adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. These risks are not exhaustive, the Company faces known and unknown risks. Additional risks and factors that may affect results of the Company are set forth in the Company's filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from the Company's expectations in any forward-looking statement. Readers are cautioned not to place undue reliance upon any forward-looking statements, including but not limited to statements about the effectuation of the Reverse Stock Split. These reports and filings are available at www.sec.gov and are available for download, free of charge, soon after such reports are filed with or furnished to the SEC, on the &#34;Investors&#34; page of the Company's website at www.apvotherapeutics.com. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, the Company does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.</p>
<div class="lb-trans"><p>本新闻稿包含 “前瞻性声明”，包括管理层对公司未来预期、计划和前景的看法，符合联邦证券法下的安全港条款，包括 1995 年《私人证券诉讼改革法》。诸如 “期望”、“估计”、“预测”、“预算”、“展望”、“预期”、“打算”、“计划”、“可能”、“将”、“能够”、“应该”、“相信”、“预测”、“潜在”、“继续” 等类似表达旨在识别此类前瞻性声明。这些前瞻性声明涉及重大风险和不确定性，可能导致实际结果与预期结果存在重大差异，因此，您不应将这些前瞻性声明视为未来事件的预测。这些前瞻性声明及可能导致此类差异的因素包括但不限于我们作为持续经营实体的能力；Aptevo 的业务或前景恶化；对初步或中期数据的进一步评估或后续临床试验的不同结果；临床开发中的不良事件和意外问题及不利进展，包括在临床试验中观察到的意外安全问题；以及监管、社会、宏观经济和政治条件的变化。这些风险并非详尽无遗，公司面临已知和未知的风险。可能影响公司结果的其他风险和因素在公司向 SEC 提交的文件中列出，包括截至 2024 年 12 月 31 日的财政年度的 10-K 表格年度报告及其后续的 10-Q 表格和 8-K 表格当前报告。上述内容列出了许多但不是全部可能导致实际结果与公司在任何前瞻性声明中的预期存在差异的因素。提醒读者不要对任何前瞻性声明过度依赖，包括但不限于关于实施反向股票拆分的声明。这些报告和文件可在 www.sec.gov 上获取，并在这些报告提交或提供给 SEC 后不久可在公司网站的 “投资者” 页面 www.apvotherapeutics.com 上免费下载。任何前瞻性声明仅在本新闻稿发布之日有效，除法律要求外，公司不承担更新任何前瞻性声明以反映新信息、事件或情况的义务。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Miriam Weber Miller</p>
<div class="lb-trans"><p>米里亚姆·韦伯·米勒</p>
</div><p>Head, Investor Relations &amp; Corporate Communications</p>
<div class="lb-trans"><p>投资者关系与企业传播负责人</p>
</div><p>Aptevo Therapeutics</p>
<div class="lb-trans"><p>Aptevo Therapeutics</p>
</div><p>Email: <strong>IR@apvo.com</strong> or <strong>Millerm@apvo.com</strong></p>
<div class="lb-trans"><p>电子邮件：<strong>IR@apvo.com</strong> 或 <strong>Millerm@apvo.com</strong></p>
</div><p>Phone: 206-859-6628</p>
<div class="lb-trans"><p>电话：206-859-6628</p>
</div><p><strong>SOURCE:</strong> Aptevo Therapeutics</p>
<div class="lb-trans"><p><strong>来源：</strong> Aptevo Therapeutics</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMTIzMw" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1121233"/></p>

Aptevo Therapeutics 宣布进行 1 比 18 的反向股票拆分 | APVO 股票新闻